GSK Touts Strong Q3 Performance on the Back of Arexvy, Shingrix Sales

In its third-quarter earnings report posted Wednesday, GSK touted 10% growth in total sales, driven largely by its vaccines business—particularly its recently launched respiratory syncytial virus shot Arexvy.